[New drug approval: Tebentafusp for treatment of metastatic uveal melanoma HLA A*02:01-positive patients]

Bull Cancer. 2023 Jan;110(1):9-10. doi: 10.1016/j.bulcan.2022.10.001. Epub 2022 Nov 7.
[Article in French]
No abstract available

Keywords: HLA; Immunotherapy; Immunothérapie; Liver metastases; Mélanome de l’uvée; Métastases hépatiques; Uveal melanoma.

Publication types

  • Letter

MeSH terms

  • Drug Approval
  • HLA-A Antigens
  • Humans
  • Liver Neoplasms* / secondary
  • Melanoma* / pathology
  • Uveal Neoplasms* / drug therapy
  • Uveal Neoplasms* / pathology

Substances

  • tebentafusp
  • HLA-A Antigens

Supplementary concepts

  • Uveal melanoma